Empagliflozin/linagliptin

Empagliflozin/linagliptin is a combination medication used in the treatment of Type 2 diabetes. It contains two active ingredients, empagliflozin and linagliptin, which work together to control blood sugar levels in people with diabetes.

Mechanism of Action[edit]

Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion and lower blood glucose levels. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the levels of incretin hormones, which help to control blood sugar by increasing insulin release, especially after a meal.

Indications[edit]

Empagliflozin/linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes who are not adequately controlled on a regimen containing empagliflozin or linagliptin, or in patients already being treated with both empagliflozin and linagliptin.

Side Effects[edit]

Common side effects of empagliflozin/linagliptin include urinary tract infections, upper respiratory tract infections, and increased urination. Serious side effects may include hypoglycemia, acute kidney injury, and hypersensitivity reactions.

Contraindications[edit]

Empagliflozin/linagliptin is contraindicated in patients with a history of serious hypersensitivity reaction to empagliflozin, linagliptin, or any of the product components. It is also contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis.

Drug Interactions[edit]

Empagliflozin/linagliptin may interact with other medications, including diuretics, insulin or insulin secretagogues, and rifampin.

Dosage and Administration[edit]

The recommended dose of empagliflozin/linagliptin is one tablet taken orally once daily in the morning, with or without food.